Frank Reed

With a reverse stock split, Idaho Copper is making a bold play for the NYSE to unlock capital for its world-class copper and molybdenum deposit.

A multi-faceted campaign by ACE Cash Express leverages customer spending and employee generosity to provide vital supplies for teachers across seven states.

Sweeping reforms pulled Florida's property insurance market from the brink of collapse. We decode the fixes, the capital influx, and the risks that still loom.

General Mills launches a major playoff campaign with Justin Jefferson and Terry Crews, betting on star power and savings to score big with consumers.

Amid a $2.37B buyout, Weiss Asset Management's increased stake in Avadel Pharma raises questions. Is it a vote of confidence or a strategic power play?

Hedge fund Balyasny Asset Management builds a 1.72% stake in JTC plc, signaling high-stakes maneuvering in the £2.3 billion takeover saga.

Boston's Weiss Asset Management reveals a strategic 4.17% derivative stake in International Personal Finance as a takeover deadline looms.

A hedge fund's disclosure reveals a puzzling short position and a fresh stock purchase in American Axle, hinting at a high-stakes arbitrage play.

Weiss Asset Management builds a major stake in International Personal Finance using only derivatives, signaling a new era of high-stakes M&A battles.

A $2.4B deal for Alphawave IP and a revealing investor filing pull back the curtain on the high-stakes race to build the infrastructure for an AI world.

A regulatory filing reveals a key investor's move in the Avadel bidding war, exposing the intense M&A hunger driving the future of health tech.

A major hedge fund's move in a $2.4B semiconductor deal reveals a critical truth: the future of precision medicine is built on high-speed data infrastructure.

Hedge fund Balyasny reveals a 1.26% economic stake in Just Group via derivatives, shining a light on the complex strategies at play in its takeover.

A regulatory filing reveals a key investor's move as Alkermes' $2.1B bid for Avadel and its blockbuster narcolepsy drug, LUMRYZ, nears its final act.

A $2.4B deal for AI's future. A hedge fund's strategic play. We decode the battle for Alphawave, the company powering the next tech revolution.

A $2.4B semiconductor deal seems distant from medicine, but it's forging the AI hardware backbone for the next generation of precision health.

Regulatory filings reveal Balyasny Asset Management's strategic trades in Avadel Pharma, offering a glimpse into the high-stakes bidding war with Alkermes.

Balyasny Asset Management's complex derivative stake in JTC plc reveals the hidden strategies shaping a major takeover and the capital flows funding innovation.

A mandatory filing reveals hedge fund Balyasny's 1.26% CFD stake in Just Group, offering a rare glimpse into high-stakes M&A strategy and regulation.

A regulatory filing from Balyasny Asset Management reveals intense investor activity as a bidding war for narcolepsy drugmaker Avadel heats up.